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Summary Box 
 
 What is the key question?  
Is long-term exposure to traffic or ambient air pollution associated with prevalence 
of cough and phlegm in adult European populations?  
 What is the bottom line? 
Current long-term average air pollution levels were not associated with symptoms of 
chronic bronchitis, cough or phlegm in European adults of all ages living in nine 
European countries, but there were small increases in reported phlegm in never 
smokers associated with coarse particulate matter.  
 Why read on?  
This is one of the largest such studies in adults involving  >10,000 individuals in five 
European cohorts using harmonised exposure and outcome measurements; while 
most results were null, there was some heterogeneity across findings for cohort 
assessments at different time points, particularly for black carbon and NO2.   
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Abstract  
 
Background: This study aimed to assess associations of outdoor air pollution on prevalence of 
chronic bronchitis symptoms in adults in five cohort studies (Asthma-E3N, ECRHS, NSHD, SALIA, 
SAPALDIA) participating in the European Study of Cohorts for Air Pollution Effects (ESCAPE) project.  
 
Methods: Annual average particulate matter (PM10, PM2.5, PMabsorbance, PMcoarse), NO2, NOx and road 
traffic measures modelled from ESCAPE measurement campaigns 2008-11 were assigned to home 
address at most recent assessments (1998-2011). Symptoms examined were chronic bronchitis 
(cough and phlegm for ≥3 months of the year for ≥2 years); chronic cough (with/without phlegm); 
and chronic phlegm (with/without cough). Cohort-specific cross-sectional multivariable logistic 
regression analyses were conducted using common confounder sets (age, sex, smoking, interview 
season, education), followed by meta-analysis.   
  
Results: 15279 and 10537 participants respectively were included in the main NO2 and PM analyses  
at assessments in 1998-2011.  Overall, there were no statistically significant associations with any air 
pollutant or traffic exposure. Sensitivity analyses including in asthmatics only, females only, or using 
back-extrapolated NO2 and PM10 for assessments in 1985-2002 (ECRHS, NSHD, SALIA, SAPALDIA), did 
not alter conclusions.   In never-smokers, all associations were positive, but reached statistical 
significance only for chronic phlegm with PMcoarse OR 1.31 (1.05-1.64) per 5 µg/m3 increase and PM10  
with similar effect size. Sensitivity analyses of older cohorts showed increased risk of chronic cough 
with PM2.5abs (black carbon) exposures. 
 
Conclusions: Results do not show consistent associations between chronic bronchitis symptoms and 
current traffic-related air pollution in adult European populations. 
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INTRODUCTION 
 
Chronic cough and phlegm production are common respiratory symptoms. In the past these were 
often considered together as the clinical phenotype of chronic bronchitis(1), but more recently 
phlegm(2) and cough(3) have been considered separately and may have differing mechanisms – for 
example, cough may result from central reflex sensitivity(4) as well as irritation and inflammation. A 
previous study of young adults found wide geographic variability in chronic bronchitis prevalence 
(0.7%-9.7%) across Europe but only 30% of the variability could be explained by differences in 
smoking habits(5). This suggests other potentially modifiable factors – such as air pollution – may be 
important.   
 
There is good evidence that air pollution triggers exacerbations in COPD patients, and suggestive 
evidence of chronic effects of air pollution on the prevalence and incidence of COPD in adults(6). 
Concurrent asthma may give rise to cough and phlegm. Traffic-related air pollution has also been 
related to onset of childhood asthma, but findings in adults are less clear(7).Pathophysiological 
studies() have found associations between long-term exposure to ambient particulate matter (PM) 
and chronic mucosal inflammation in the lung(8), resulting in excessive mucus secretion, coughing 
and phlegm production(9). Previous epidemiological studies examining associations between 
objectively measured air pollution and chronic bronchitis symptoms in adults(10-27) are difficult to 
compare  . For example,   some studies have used surrogate measures for air pollution (e.g. distance 
from the main road(13,20,21,27), traffic intensity(17)),  others  used air pollution data from local 
monitoring networks(10-13,16,22,23,25,26), or model-derived exposures estimated at home 
address(15,17,19,24). Some(13,15,17) but not all(14,18,19,23) studies reported increased risks in the general 
population, whereas  studies in specific populations reported associations only in never-smokers(10-
12,16,26) or females(20,21,25).  
 
The present study investigates cross-sectional associations between ambient air pollution estimated 
at home address and prevalence of chronic bronchitis symptoms in five European cohort studies 
participating in ESCAPE (European Study of Cohorts for Air Pollution Effects) project. Taking 
advantage of individual information and repeated assessments, we gave special attention to the 
time period of exposure (contemporary, historic 2000s and historic 1990s exposures) in repeated 
cross-sectional analyses and conducted extensive sensitivity analyses.  
 
METHODS 
 
Study populations 
Analyses were based on subpopulations from the European Community Respiratory Health Survey 
(ECRHS), National Survey of Health and Development (NSHD) from UK, the Study on the influence of 
Air pollution on Lung function, Inflammation and Aging (SALIA) from Ruhr area in Germany, the 
Swiss cohort study on Air Pollution And Lung and heart Diseases in Adults, SAPALDIA, and the French 
Asthma-E3N study, an asthma case-control study nested in the “Etude Épidémiologique de Femmes 
de la Mutuelle Générale de l'Education Nationale (E3N)” cohort   who were living in geographic areas 
covered by ESCAPE exposure models (“ESCAPE areas”). A brief description of each cohort is available 
in online supplements-1. Those included in the analyses had valid chronic bronchitis data and 
information on sex, age, smoking status, season of questionnaire interview, education.  The NSHD, 
SALIA and SAPALDIA contributed information from two assessment rounds Ethical approvals for 
analyses were obtained for all cohorts.  
 
Outcome definition   
Chronic bronchitis symptoms were assessed by questionnaire in all cohorts using standard questions 
based on those defined by the British Medical Research Council (MRC) in 1965[1], as reported cough 
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AND phlegm production first thing in the morning and/or during the day or at night for three 
months of the year for ≥2 years. Other outcomes investigated were chronic cough (reported cough 
for 3 months for ≥2 years regardless of reported phlegm or not) and chronic phlegm (reported 
phlegm for 3 months for ≥2 years regardless of reported cough or not), except for SALIA, where 
questions regarding phlegm production were not asked separately from cough, therefore it was not 
possible to derive the outcome of “chronic phlegm” (online supplements-2).  
 
Exposure measurements  
 
ESCAPE-period exposures  
 
The ESCAPE exposure assessments have been described elsewhere(28-29). Briefly, a standardised 
protocol was applied in all geographic sites within the ESCAPE areas during October 2008 to April 
2011. Nitrogen dioxide (NO2) and nitrogen oxides (NOX) measurements were conducted in 36 
ESCAPE study areas while PM (PM10, particulate matter with aerodynamic diameter ≤10µm & PM2.5, 
particulate matter with aerodynamic diameter ≤2.5µm) were measured in 20 ESCAPE study areas, 
both in a 14-day period of each of three seasons (cold, warm and intermediate). Annual average 
concentrations for each monitoring site were calculated by combining the three 14-day periods with 
measurement data from a centrally located reference site, in operation during the whole study 
period, to adjust for temporal variability. The Land Use Regression (LUR) model developed used 
Geographic Information System (GIS)-derived predictor variables to describe spatial variation of 
annual average concentrations for each study area at measurement locations. An annual average 
estimate was then assigned from the LUR models to each geocoded address (place of residence) 
based on the date of questionnaire assessment for study participants. In addition, two indicators of 
local exposures to traffic were derived for each participant’s address:  traffic intensity on the nearest 
road (Traffic intensity, vehicles/day) and total traffic load on major roads in a 100 metre buffer 
(Traffic load, vehicles*m/day).      
 
Each participant was assigned an annual average concentration at home outdoor of NO2, NOX and 
the background levels of NO2. For participants residing within ESCAPE areas with PM measurements, 
they were also assigned exposures to PM2.5, PM10, the coarse fraction of PM (PMcoarse as PM10 minus 
PM2.5) and PM2.5abs , the light absorbance of PM2.5 (similar to “black carbon”).    
 
Back-extrapolation   
 
Questionnaire assessments in some cohorts occurred prior to the ESCAPE monitoring campaign in 
2008-11, with some up to 25 years earlier. Due to changes (usually decreases) in air pollution over 
time, ESCAPE-period exposure values were back-extrapolated to the years of collection of health 
data  assuming proportional changes in within-city spatial patterns.  Here, individually assigned 
estimates of ambient concentrations were adjusted (calibrated) for the long-term trends using a pre-
defined back-extrapolation algorithm (see 
http://www.escapeproject.eu/manuals/Procedure_for_extrapolation_back_in_time.pdf accessed 10 
May 2014).  
 
Back-extrapolation for NO2 and PM10 was conducted by ratio methods to the most recent follow-up 
years in ECRHS and SAPALDIA (assessments in 1998-2002 and 2002 respectively) and   also   to 
earlier assessment in SALIA in 1985-94, NSHD in 1999, and SAPALDIA in 1991.    
 
Statistical analyses 
Each cohort was first analysed separately using centrally written analytic codes, and harmonised 
outcome and confounder variables. Descriptive analyses were conducted including Spearman 
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correlation coefficients. The analytic strategy, including all models, sensitivity and subgroup 
analyses, was specified a priori, based on current knowledge. Cross-sectional analyses using logistic 
regression models were undertaken to obtain cohort-specific Odds Ratios (ORs). Results were then 
combined using both fixed effects and random effects meta-analyses; pooled estimates from the 
latter were only shown when heterogeneity (p-value<0.05) existed across cohorts.   
 
The main analyses used ‘ESCAPE-period exposure’ for 2008-11 applied to the most recent 
assessment within 10 years of exposure models in all five cohorts (earliest ECRHS and SAPALDIA with 
assessments in 2002).  
 
A sequence of nested models were run for each outcome: Model 1 - unadjusted crude model; Model 
2 - adjustments of age and sex; Model 3 (Main Model) – further adjusted for smoking, education 
level and interview season, all  uniformly defined in all cohorts. Model 4 was further adjusted for 
environmental tobacco smoking (ETS) exposures at home and/or at work and occupational 
exposures to any of vapours/gases/dusts/fumes (VGDF); availability and definition of these differed 
across cohorts. Model 5 was a study-specific model further adjusted for smoking pack years and 
locally defined neighbourhood-level socioeconomic status. All traffic indicators models were 
adjusted for the background NO2 (NO2 not directly influenced by traffic) to better estimate near 
traffic effects.   
 
In main analyses, based on Model 3 using ESCAPE-period exposures, cohort-specific sensitivity 
analyses were conducted (i) on the following potentially sensitive subgroups:  females, asthmatics, 
those aged >=50 years and  never smokers; (ii) excluding those with COPD (Chronic Obstructive 
Pulmonary Disease) and/or asthma. .   
 
All cohort-specific results from Model 3 (or where appropriate, related subgroup and/or sensitivity 
analyses), were then combined using both fixed effects and random effect meta-analyses by the 
Stata metan command; pooled estimates from the latter were only shown when heterogeneity (p-
value<0.05) existed across cohorts. Results presented/used in the meta-analyses for multi-country 
study ECRHS were from random effect models with city modelled as a random effect while the other 
four were from fixed effect models with country/area modelled as a fixed effect.   
 
Further sensitivity analyses were conducted to address issues relating to cohort heterogeneity and 
exposure estimation. In main analyses, based on Model 3 using ESCAPE-period exposures, cohort 
heterogeneity was investigated in leave-one-out meta-analyses, where each cohort was dropped in 
turn. To investigate exposure issues we (i) conducted meta-analyses excluding centres with poorer 
exposure model validation statistics (R2 <0.6)  (ii) restricted analyses to non-movers (those who did 
not move between the most recent and previous assessment, which were at least 8 years apart) (iii) 
conducted analyses using ‘contemporary exposure estimates’; these used ESCAPE 2008-11 
estimates for Asthma-E3N (2011), NSHD (2008) and SALIA (2006/10) i.e. excluding SAPALDIA and 
ECHRHS where questionnaire assessments were >6 years prior to exposure estimation (iv) 
conducted analyses using ‘historic exposure estimates’ back-extrapolated to year of assessment for 
assessments in 1999-2002 (ECRHS 2002, NSHD 1999, SAPALDIA 2002) and in the early 1990s ( 
SAPALDIA 1991, SALIA 1985-94) i.e. when exposures were higher. 
 
 
Statistical analyses were performed using Stata 12.0, Texas, USA. Statistical significance was set at p-
value <0.05. 
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RESULTS 
 
For main analyses using ESCAPE-period estimates for the most recent assessment, there were 15279 
participants successfully assigned at least NO2 estimates (Table 1) and 10537 participants assigned at 
least PM10 estimates (see online supplements-3) with information on variables of Main model 3. At 
the most recent assessment, mean age of the study population ranged from 42.9 years (ECRHS) to 
71.5 years (SALIA). Asthma-E3N and SALIA were cohorts of older females only. Current smokers 
ranged from 5.3% (SALIA) to 32% in the younger general population of ECRHS. Asthma-E3N 
participants were mainly teachers, and 91.3% were highly-educated compared with 11.5% in NSHD. . 
VGDF exposure was   30-40% in the mixed sex general population cohorts (ECRHS, NSHD, SAPALDIA) 
but lower in the female cohorts. Prevalence of chronic bronchitis ranged from 1.5% (Asthma-E3N) to 
6.8% (SALIA) (online supplements-4).  
  
Summary statistics of ESCAPE period air pollutants and traffic indicators are presented in online 
supplements-5.   Mean NO2 ranged from 22 µg/m3 (NSHD) to 31 µg/m3 (Asthma-E3N) whereas mean 
PM10 ranged from 16 µg/m3 (NSHD) to 27 µg/m3 (SALIA).  Within-study contrasts assessed by IQR 
varied from 8 µg/m3 in SAPALDIA to 20 µg/m3 in ECRHS for NO2 and2 µg/m3 (NSHD) to 9.2 µg/m3 
(ECRHS) for PM10. Exposures back-extrapolated to the 1990s   were higher than for estimates at later 
assessments. 
 
Spearman correlation coefficients between PM and NOx/NO2 metrics were high (r~0.7-0.8) therefore 
precluding two pollutant analyses, while correlations between pollutants and traffic measures were 
low to moderate (r~0.3-0.5) (online supplements-6).  
 
ESCAPE-period exposures estimates 2008-11 were highly correlated (r>0.9) with exposures back-
extrapolated to the assessments in 2002 ECRHS and SAPALDIA, justifying the use of ESCAPE-period 
exposures in main analyses.   
 
 Results from analyses using ESCAPE-period exposure estimates 
 
Combined estimates from the   meta-analyses using Model 3 are displayed in Table 2 (see also 
Figure 1 and Forest plots, online supplements-7). No statistically significant overall associations were 
found between any air pollutant or traffic indicator and any outcome using ESCAPE period estimates.     
 
Associations in meta-analyses using main Model 3 leaving out one cohort in turn (online 
supplements-8) or restricted to cohorts with ‘contemporary exposure estimates’: Asthma-E3N 
(2011), NSHD (2008) and SALIA (2006-10) (online supplements-9), were all null except for 
associations between chronic cough and PM2.5abs in analyses not including ECRHS, with OR, 95%CI 
1.20 (1.01-1.44) per 10-5/m.   
 
Further adjustments in Model 4 and 5 did not change the results substantially, although   effect 
estimates were slightly smaller and the 95% confidence intervals (CI) became wider (data not 
shown), which may in part relate to fewer participants.  
Sensitive subgroups  
 
In never-smokers, higher and uniformly positive effect estimates for all air pollutants and traffic 
indicators for all three outcomes were observed (Table 3). A statistically significant association was 
found between chronic phlegm and both PM10 (OR, 95%CI: 1.32(1.02-1.71), per 10 µg/m3 increase) 
and PMcoarse (OR, 95%CI: 1.31(1.05-1.64), per 5 µg/m3 increase) (Figure 2).  In analyses of never-
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smokers in cohorts with ‘contemporary exposure estimates’ (online supplements-9), associations 
with chronic phlegm were no longer statistically significant but associations between chronic cough 
and PM2.5 and PM2.5abs became larger and statistically significant: PM2.5 OR, 95%CI: 1.47 (1.02-2.12) 
per 5 µg/m3 increase, PM2.5abs OR, 95%CI: 1.30 (1.04-1.63) per 10-5/m, albeit with evidence of 
heterogeneity for the latter (Phet=0.024). In the random-effects analysis, the PM2.5abs result was not 
statistically significant: OR, 95%CI 1.58 (0.90-2.76) per 10-5/m.  
There were no statistically significant effect estimates observed in meta-analyses for asthmatics, 
females, participants aged 50+ years, participants without COPD and/or asthma, or non-movers 
(results not shown).     
 Exposure-related sensitivity analyses 
 
Sensitivity analyses for NO2 and NOx excluding centres with LUR model validation R2 statistics<0.6 
gave similar null results for the main ESCAPE-period analyses (online supplements-10). The R2 
statistics were all>0.6 for PM estimates in our study areas.  
 
Using back-extrapolated ‘historic exposure estimates’ to 1999-2002 (Table 4), there were consistent 
but statistically non-significant elevated risks in all populations but not in never-smokers for all three 
outcomes with NO2 and PM10. Using historic exposure estimates to the early 1990s in only two 
cohorts (Table 5), statistically significant associations were found between NO2 and both chronic 
bronchitis (OR: 1.10, 95%CI: 1.00-1.22) and chronic cough (OR: 1.10, 95%CI: 1.01-1.20). 
 
 
DISCUSSION 
 
This is one of the largest studies to investigate the link between bronchitis symptoms and current air 
pollution exposures using five cohorts in   nine European countries. Main analyses defined a priori 
did not show significant associations between the period prevalence of chronic bronchitis, cough or 
phlegm and any of six air pollutant metrics and two traffic indicators. Associations between the 
particulate measure of black carbon PM2.5abs and chronic cough were statistically significant if leaving 
out a younger cohort (ECRHS) in analyses of all individuals and of never-smokers. In never smokers, 
associations were in general larger and consistently positive, reaching statistical significance 
between phlegm and PMcoarse (but not PM2.5). The higher NO2 exposures in the early 1990s were 
associated with chronic bronchitis and cough, but this analysis was only possible for two cohorts.  
 
Findings in comparisons with previous studies 
 
To our knowledge, this is one of the first epidemiological studies to report on long-term associations 
between the coarse fraction of ambient particles and cough and phlegm in adults. PMcoarse has 
previously been found to be associated with respiratory hospital admissions(30) and to be more 
potent than fine PM in inducing inflammatory responses in in vitro and in vivo (mouse) studies(31-32).  
     
We also observed significant associations between PM10 and phlegm in never-smokers but not 
overall.  As in this analysis, cross-sectional associations with chronic bronchitis and with phlegm 
were seen in never smokers (but not in former and current smokers) in the SAPALDIA study(26), but 
no statistically significant associations were seen in SALIA (mainly non-smokers)(23) while continuous 
measures of PM10 were not associated with cough in   older adults in France(15). However, 
longitudinal analyses in  both  SALIA(22) and SAPALDIA(24) studies suggested declines in PM10 are 
associated with declines in cough and chronic bronchitis symptoms; additionally an analysis of 
9 
 
Seventh Day Adventist non-smokers found associations between chronic cough and 15 year 
cumulative PM10 exposures(10).    
 
We saw no significant associations overall with PM2.5. This is consistent with previous cross-sectional 
epidemiological studies in adults in the USA(19) and a 2006 analysis of the ECRHS(25) cohort and with a 
longitudinal analysis in Melbourne(14but not an analysis in non-smoking Seventh Day Adventists 
found associations between 20 year cumulative exposure to PM2.5 and chronic bronchitis(11). We did 
observe associations between chronic cough and PM2.5abs, a measure of black carbon or soot, in 
some sensitivity analyses, but these were not consistent and may represent chance findings.  
 
Lack of findings of significant associations with NO2, except for chronic cough and chronic bronchitis 
in (SALIA and SAPALDIA) the 1990s when exposures were higher are partially consistent with 
previous studies. Significant associations were seen with cough, but not chronic bronchitis in a 
previous analysis of SALIA(23); with chronic bronchitis and with phlegm in women but not men in the 
ECRHS (cough was not considered)(25); with phlegm (but not cough) in women but not men in an 
older French cohort(15); and with chronic bronchitis and chronic phlegm in never smokers in 
SAPALDIA(26). Chronic bronchitis symptoms were not associated with low levels of cumulative NO2 
exposure in non-smoking Californians(16).  
 
We are aware of only one adult study that has considered NOx and contrary to our null findings, 
exposures >19 vs. 0-8 µg/m3 in southern Sweden were associated with   higher prevalences of 
chronic bronchitis(17). 
 
We found no significant associations of traffic intensity with any chronic bronchitis symptoms, 
contrary to six previous studies using differing traffic intensity metrics based on traffic counts (17,23) 
and distance from road(13,20,21,27).  
 
Odds ratios using ESCAPE exposure estimates in individual cohorts were comparable with those from 
previously published analyses using cohort-specific air pollution estimates, allowing for differences 
in study design (see online supplements-11 for details). 
 
Most(10-13,15-17,19-21,23,25-27) but not all(14,18,22,24) previous studies examining associations between air 
pollutant metrics and chronic bronchitis in adults have conducted cross-sectional analyses. We did 
not do a longitudinal analysis because symptoms come and go over time and they do not represent a 
stable chronic condition. Also, questionnaire-based reporting is most likely to capture symptoms 
experienced in the last few months therefore reflecting cumulative prevalence of acute and sub-
acute effects.    
 
Strengths and weaknesses of the study  
 
Strengths of this study are the use of five large existing cohorts in different parts of Europe, centrally 
defined harmonised variables for each cohort, standard assessment of exposures to eight traffic-
related exposures individually-assigned to home address and an identical pre-specified statistical 
protocol. However, there were also several limitations. Firstly,   uncertainty in   exposure estimates 
might have introduced non-systematic errors, reducing the power of the study to detect effects. 
However, analyses excluding models with spatial variation R2<0.6 did not substantially change the 
results (online supplements-10 and supplements-12) Secondly, exposure assessments for ESCAPE 
occurred years after questionnaire assessments in some cohorts. This was investigated using back-
extrapolated exposure assessments aligned with questionnaire. Back-extrapolation assumes within-
city spatial contrasts of air pollutants remain similar over long periods of time, for which there is 
some support from previous studies(33-34). Thirdly, harmonised information on confounders was 
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limited. Fourthly, there might be reporting bias, particularly reluctance to report phlegm in 
females(35). Fifthly, we conducted many statistical analyses and it is possible that observed 
associations were due to chance. Sixthly, the cohorts were heterogeneous in both design and 
populations, which may have resulted in systematic differences between studies. To address this, we 
used harmonised variables, explored potential effect modifiers, used meta-analyses not pooled 
analyses and, conducted leave-one-out sensitivity meta-analyses. Finally, we note that detecting 
effects in potential susceptible subgroups, of relevance to environmental policy, may require much 
larger sample sizes than possible here.  
 
In conclusion, although deleterious effects of ambient air pollution on a range of health outcomes 
including mortality are well documented, we did not find evidence for significant associations 
between  current long-term average air pollution levels and   symptoms of chronic bronchitis, cough 
or phlegm in >10,000 European adults. Our study findings, based on very large-scale harmonised 
population-based cohort studies using a priori specified analyses, contribute to strengthening the 
evidence-based for policy formulation.  
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Table 1  Description of study population (sub-populations of the original study with individually assigned NO2 measures) of all five cohorts as used at each 
assessment. The table shows the N (and % of N) for categorical variables and Mean (standard deviation,SD) for continuous variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ETS = Environmmental Tobacco Smoke at home and/or at work ; VGDF = occupational vapour/gases/dust/fumes exposure(any of). 
*calculations based on ex-smokers and current smokers. 
**Asthmatics cases were defined as those who answered “yes” to ever-asthma questions in the questionnaires of all cohorts. 
***Stages of COPD were classified according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) definitions and NHANES III (Third National Health and Nutrition Examination Survey) reference 
equations. There were no lung function test conducted in Asthma-E3N cohort hence results were n/a (not applicable). Only pre-bronchodilator spirometric measurements were available for all coho 
Study Asthma-E3N ECRHS NSHD SALIA SAPALDIA 
Co-variables Assessment 
2011 
N=4070 
 Assessment 
1998-2002 
N=5053 
Assessment 
1999 
 N=2322 
 Assessment 
2008 
N=2024 
Assessment 
1985-1994 
 N=4360 
 Assessment 
2006-2010  
N=2019 
 Assessment  
1991 
N=3766 
 Assessment   
2002 
 N=2113 
 N / 
Mean 
%  
/SD 
N / 
Mean 
%  
/SD 
N / 
Mean 
%  
/SD 
N / 
Mean 
%  
/SD 
N / 
Mean 
%  
/SD 
N / 
Mean 
%  
/SD 
N / 
Mean 
%  
/SD 
N / 
Mean 
%  
/SD 
Female 4070 100% 2712 53.7% 1216 52.4% 1075 53.1% 4360 100% 2019 100% 1949 51.8% 1126 53.3% 
Age, years 70.0 6.4 42.9 7.1 53.5 0.2 61.9 0.6 54.5 0.6 71.5 3.4 41.3 11.8 53.1 11.5 
Body Mass Index 
(BMI), kg/m2 
24.0 4.5 25.7 4.6 27.4 4.7 27.9 4.9 27.6 4.7 26.9 4.3 23.7 3.9 25.5  4.3 
Smoking pack years* 3.5 10.2 12.2 18.2 10.3 13.6 10.7 15.2 4.1 10.3 4.3 11.9 11.8 19.0 13.8 22.4 
Never-smoker 2770 68.0% 2086 41.3% 708 30.5% 644 31.8% 3230 74.1% 1607 79.6% 1571 41.7% 853 40.4% 
Ex-smoker 1041 25.6% 1364 27.0% 1133 48.8% 1141 56.4% 378 8.7% 304 15.1% 809 21.5% 678 32.1% 
Current-smoker 259 6.4% 1603 31.7% 481 20.7% 239 11.8% 752 17.2% 108 5.3% 1386 36.8% 582 27.5% 
Low education  107 2.6% 1471 29.1% 965 41.6% 798 39.4% 1260 28.9% 438 21.7% 574 15.2% 137 6.5% 
Medium education  246 6.1% 1732 34.3% 1105 47.6% 994 49.1% 2100 48.2% 986 48.8% 2410 64.0% 1352 64.0% 
High education  3717 91.3% 1850 36.6% 252 10.9% 232 11.5% 1000 22.9% 595 29.5% 782 20.8% 624 29.5% 
ETS exposures   168 5.1% 506 10.0% 523 25.0% 452 24.6% 2205 50.9% 976 49.2% 518 13.8% 146 6.9% 
VGDF exposures 879 23.2% 2146 44.4% 721 35.1% 632 34.8% 428 9.8% 184 9.1% 1060 28.2% 581 27.5% 
Asthmatics** 967 26.6% 782 15.5% 221 10.0% 192 9.8% 102 2.4% 121 6.4% 296 7.9% 181 8.6% 
COPD Gold stage 1 
plus*** 
n/a n/a 305 7.2% 110 6.6% 92 8.2% 289 12.5% 102 15.4% 395 11.4% 399 20.6% 
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Table 2 Overall populations at the most recent assessment *: fixed-effect meta-analysis results on Model 3 (adjusted for age, sex, smoking, education and 
season of interview) for all air pollutants and traffic indicators for each outcome, using ESCAPE-period (2008-2011) exposures from all five cohorts.  
Outcome Chronic bronchitis   Chronic cough Chronic phlegm 
Exposure[1] OR Phet [2] OR Phet OR Phet 
(95%CI) (95%CI) (95%CI) 
PM2.5 , (5µg/m3) 0.90 0.754 0.91 0.440 0.96 0.850 
(0.74-1.09) (0.80-1.04) (0.84-1.11) 
PM2.5abs, (per 10-5*m-1) 1.02 0.504 1.01 0.070 1.02 0.693 
 (0.85-1.22) (0.89-1.15) (0.88-1.18) 
PM10, (10µg/m3) 0.92 0.193 0.92 0.494 1.02 0.696 
(0.75-1.13) (0.80-1.06) (0.87-1.18) 
PMcoarse, (5µg/m3) 0.99 0.165 0.99 0.737 1.07 0.131 
(0.83-1.18) (0.87-1.12) (0.94-1.22) 
NO2, (10µg/m3) 1.00 0.973 1.05 0.953 1.01 0.656 
(0.92-1.08) (0.99-1.11) (0.95-1.07) 
NOx , (20µg/m3) 1.02 0.793 1.04 0.622 1.02 0.393 
(0.94-1.09) (0.98-1.09) (0.96-1.08) 
Traffic intensity[3] 0.95 0.739 0.96 0.339 0.98 0.366 
(0.75-1.19) (0.80-1.14) (0.82-1.17) 
Traffic Load[4] 0.99 0.509 0.95 0.831 0.97 0.797 
(0.82-1.20) (0.81-1.10) (0.83-1.13) 
* Asthma-E3N 2011, ECRHS  1998-2002, NSHD 2008, SALIA  2006-10, SAPALDIA 2002.  Due to questionnaire wording SALIA is not included in analyses of phlegm alone.     
[1]: Results were interpreted as per Exposure unit, as shown in the bracket.                                                                                                                                                                                                                
[2]: Phet:  P-value for heterogeneity. 
[3]: Binary variable, <5,000 (reference group) vs. >5,000 vehs/day.  
[4]: Binary variable, <500,000 (reference group) vs. >500,000 vehs*m /day.  
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Table 3 Never-smokers at the most recent assessment*: fixed-effect meta-analysis results on Model 3 (adjusted for age, sex, smoking, education and season 
of interview) for all air pollutants and traffic indicators for each outcome, using ESCAPE-period (2008-2011) exposures   from all five cohorts.  
Outcome Chronic bronchitis   Chronic cough Chronic phlegm 
Exposure[1] OR Phet [2] OR Phet OR Phet 
(95%CI) (95%CI) (95%CI) 
PM2.5 , (5µg/m3) 1.28 0.488 1.11 0.091 1.16 0.519 
 (0.95-1.72) (0.90-1.36)  (0.91-1.48) 
PM2.5abs, (per 10-5*m-1) 1.20 0.233 1.16 0.032 1.10 0.602 
 (0.92-1.57) (0.96-1.39) (0.87-1.39) 
   1.27ⱡ 
(0.88-1.85) 
   
PM10, (10µg/m3) 1.35 0.763 1.08 0.535 1.32 0.474 
 (0.97-1.88) (0.86-1.35) (1.02-1.71) 
PMcoarse, (5µg/m3) 1.15 0.979 1.06 0.954 1.31 0.457 
 (0.87-1.53) (0.87-1.29) (1.05-1.64) 
NO2, (10µg/m3) 1.06 0.440 1.04 0.088 1.02 0.234 
 (0.93-1.20) (0.97-1.12) (0.92-1.13) 
NOx , (20µg/m3) 1.09 0.151 1.04 0.021 1.05 0.121 
 (0.93-1.28) (0.97-1.12)  (0.96-1.15) 
   1.06ⱡ 
(0.91-1.23) 
   
Traffic intensity[3] 1.12 0.763 1.07 0.629 1.04 0.830 
(0.79-1.57) (0.84-1.37) (0.80-1.37) 
Traffic Load[4] 1.11 0.354 1.03 0.51 1.02 0.422 
(0.83-1.49) (0.82-1.29) (0.79-1.32) 
* Asthma-E3N 2011, ECRHS 1998-2002, NSHD 2008, SALIA 2006-10, SAPALDIA 2002.  Due to questionnaire wording SALIA (>70% never-smokers) is not included in analyses of phlegm alone.     
ⱡ Estimates from random-effect meta-analysis as Phet: <0.05 
[1]: Results were interpreted as per Exposure unit, as shown in the bracket.                                                                                                                                                                                                                
[2]: Phet:  P-value for heterogeneity.  
[3]: Binary variable, <5,000 (reference group) vs. >5,000 vehs/day.  
[4]: Binary variable, <500,000 (reference group) vs. >500,000 vehs*m /day. 
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Table 4: Back-extrapolated from ESCAPE-period exposures (2008-11) to early 2000s ‘historic exposure estimates’: fixed-effect meta-analysis on cross-
sectional results from ECRHS (2002), NSHD(1999), SAPALDIA (2002): all participants (upper section)and never-smokers (lower section), Main model 3.  
All participants back-extrapolated NO2, 10 µg/m3                                                                                                 back-extrapolated PM10, 10µg/m3 
 Chronic bronchitis Chronic cough  Chronic phlegm Chronic bronchitis Chronic cough  Chronic phlegm 
Cohort(year) OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI 
ECRHS(2002) 0.99 (0.90-1.10) 1.03 (0.96-1.11) 1.01 (0.94-1.09) 1.22 (0.83-1.80) 1.03 (0.80-1.34) 1.29 (0.97-1.72) 
NSHD(1999) 1.23 (0.99-1.54) 1.07 (0.91-1.27) 1.16 (0.96-1.41) 1.20 (0.57-2.53) 1.05 (0.61-1.79) 1.39 (0.74-2.61) 
SAPALDIA(2002) 1.01 (0.77-1.33) 0.99 (0.71-1.40) 0.98 (0.84-1.15) 1.44 (0.63-3.28) 1.77 (0.65-4.86) 0.93 (0.59-1.45) 
Overall effect 1.03 (0.94-1.12) 1.04 (0.97-1.11) 1.02 (0.96-1.09) 1.25 (0.91-1.71) 1.06 (0.85-1.34) 1.20 (0.96-1.50) 
Phet: 0.213  0.897  0.350  0.932  0.596  0.420  
Never-smokers 
ECRHS(2002) 0.99 (0.79-1.23) 1.00 (0.91-1.10) 0.97 (0.83-1.14) 1.92 (0.92-3.99) 1.17 (0.74-1.84) 1.95 (1.09-3.49) 
NSHD(1999) 1.04 (0.60-1.80) 0.97 (0.65-1.45) 0.84 (0.52-1.37) 1.45 (0.28-7.55) 0.71 (0.20-2.52) 1.00 (0.24-4.21) 
SAPALDIA(2002) 0.92 (0.52-1.64) 0.70 (0.34-1.44) 0.88 (0.67-1.16) 0.65 (0.10-4.37) 0.59 (0.07-4.96) 0.77 (0.35-1.70) 
Overall effect 0.99 (0.81-1.20) 0.99 (0.90-1.09) 0.94 (0.83-1.07) 1.63 (0.87-3.07) 1.08 (0.71-1.64) 1.37 (0.88-2.13) 
Phet: 0.956  0.630  0.740  0.579  0.654  0.161  
Phet:  P-value for heterogeneity 
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Table 5: Back-extrapolated from ESCAPE-period exposures (2008-11) to early 1990s ‘historic exposure estimates’: fixed-effect meta-analysis on cross-
sectional results from SALIA (1985-94), SAPALDIA (1991): all participants (upper section) and never-smokers (lower section), Main model 3.  
all participants back-extrapolated NO2, 10µg/m3 back-extrapolated PM10, 10µg/m3 
 Chronic bronchitis Chronic cough  Chronic bronchitis Chronic cough  
Cohort(year) OR 95%CI OR 95%CI OR 95%CI OR 95%CI 
SALIA(1985-94) 1.08 (0.96-1.21) 1.08 (0.98-1.20) 1.04 (0.85-1.29) 1.10 (0.92-1.33) 
SAPALDIA(1991) 1.17 (0.96-1.44) 1.17 (0.96-1.42) 1.19 (0.49-2.91) 1.16 (0.48-2.79) 
Overall effect 1.10 (1.00-1.22) 1.10 (1.01-1.20) 1.05 (0.86-1.29) 1.11 (0.92-1.33) 
Phet: 0.474  0.510  0.776  0.909  
Never-smokers         
SALIA(1985-94) 1.09 (0.94-1.26) 1.03 (0.91-1.17) 1.04 (0.80-1.35) 1.02 (0.81-1.27) 
SAPALDIA(1991) 1.24 (0.85-1.79) 1.25 (0.86-1.80) 0.90 (0.19-4.30) 0.81 (0.17-3.77) 
Overall effect 1.11 (0.97-1.27) 1.05 (0.93-1.18) 1.04 (0.80-1.34) 1.01 (0.81-1.26) 
Phet: 0.538  0.330  0.858  0.774  
Phet:  P-value for heterogeneity 
Only outcomes available for both SALIA and SAPALDIA are included – analyses of phlegm alone could not be conducted in SALIA due to questionnaire wording. 
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Figures legends 
Figure 1 Meta-analysis results on Model 3 (adjusted for age, sex, smoking, education, season of 
questionnaire interview) for NO2 (per 10 µg/m3) ,PM10 (per 10 µg/m3) and PM2.5abs (per 10-5*m-1)  for 
chronic cough at the most recent assessment using the ESCAPE-period exposures   in the overall 
populations from all five cohorts.  
 
I-squared: variation in estimated effect attributable to heterogeneity  
I-V: Inverse-Variance weighted fixed effects method 
D-L: DerSimonian-Laird random effects method 
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Figure 2   Meta-analysis results on Model 3 (adjusted for age, sex, smoking, education, season of 
questionnaire interview) for PM10 (per 10 µg/m3)   and PMcoarse (per 5 µg/m3) for chronic phlegm at 
the most recent assessment using the ESCAPE period exposures in the never smokers populations 
from four cohorts. 
 
 
I-squared: variation in estimated effect attributable to heterogeneity 
I-V: Inverse-Variance weighted fixed effects method 
D-L: DerSimonian-Laird random effects method 
The SALIA study was excluded from the above analysis because questions regarding phlegm production were not asked 
separately from cough 
 
 
